Sana Biotechnology reported a net loss of $49.4 million for the first quarter of 2025, a significant improvement compared to the $107.5 million loss in the same period last year. The company ended the quarter with $104.7 million in cash, cash equivalents, and marketable securities, with an expected cash runway into 2026. Sana highlighted positive clinical data for its type 1 diabetes program and progress in its allogeneic CAR T and in vivo CAR T pipelines.